PCF Science

Fine structural design of 3βHSD1 inhibitors for prostate cancer therapy | PNAS Prostate cancer is a global health challenge, particularly for patients resistant to the second-generation anti-androgen receptor pathway inhibitor...

Congrats Zhenfei Li and his team on his story @pnas.org on fine structural design of 3βHSD1 inhibitors for prostate cancer therapy! His work builds on many years of work on HSD3B1 genetics and metabolism in prostate cancer! @pcf-science.bsky.social 🧪https://www.pnas.org/doi/10.1073/pnas.2422267122

The 31st Annual Prostate Cancer Foundation Scientific Retreat Report Background The 31st Annual Prostate Cancer Foundation (PCF) Scientific Retreat took place in Carlsbad, CA on October 24–26, 2024. Methods The Annual PCF Scientific Retreat is the foremost internat...

PUBLISHED! The 31st Annual Prostate Cancer Foundation Scientific Retreat Report, which summarizes the cutting-edge research in #ProstateCancer & other fields presented at the 2024 @PCFnews
Retreat #PCFRetreat.

@andreamiyahira.bsky.social
onlinelibrary.wiley.com/doi/10.1002/...

Prostate Cancer Foundation 2025 PCF TACTICAL Awards Targeting Mechanisms of Lethal Prostate Cancer REQUEST FOR LETTERS OF INTENT / FULL APPLICATIONS IMPORTANT: Applying for a PCF TACTICAL Award (Therapy ACceleration To Intercept CAncer Lethality) involves a 3-stage process. PCF requires a Letter of Intent (LOI), followed by full application submission upon our invitation. Following peer review, top applicants will undergo a Zoom-based interview. The Prostate Cancer Foundation (PCF) is pleased to announce a Request for LOIs for PCF TACTICAL Awards from qualified teams of academic scientists that will specifically address the development of 21st Century therapies for lethal forms of prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world. TACTICAL Awards provide $5 - $10 Million U.S.D. per award over 3-5 years. • Support large-scale research projects concerning metastatic, lethal prostate cancer over a duration of 3-5 years. • Institutional indirect costs of up to 10% will be allowed and should be included as part of the total research budget. • Clinical trial costs are not allowed; however, correlative research to support high impact clinical trials for advanced prostate cancer is encouraged. IRB submission and preferably approval is desired at time of application.

ANNOUNCEMENT: RFA for 2025 PCF TACTICAL Award Letters Of Intent, for multi-institutional research projects to target lethal #ProstateCancer, in 6 specified topic areas.

LOI DEADLINE: May 19, 2025

View RFA: res.cloudinary.com/pcf/images/v...

View LOI form: res.cloudinary.com/pcf/images/v...

1/3 Big congrats to Justin Hwang, Emmanuel Antonarakis, @charlesryanmd.bsky.social & team on a story looking at germline HSD3B1 (which is linked to prostate cancer mortality) vs. tumor findings in prostate cancer! A couple of things that I find interesting here!🧪 www.mdpi.com/2072-6694/17...

Androgen receptor–regulated lncRNA PRCAT71 promotes AR signaling through the interaction with KHSRP in prostate cancer Long noncoding RNA PRCAT71 and RNA binding protein KHSRP stabilize androgen receptor mRNA to promote prostate cancer progression.

Thrilled to share our new study in
@ScienceAdvances
Androgen receptor–regulated lncRNA PRCAT71 promotes AR signaling through the interaction with KHSRP in prostate cancer | Science Advances www.science.org/doi/10.1126/... @pcf-science.bsky.social #lncRNA #ARsignaling #CancerResearch

Prostate Cancer Foundation 2025 PCF TACTICAL Awards Targeting Mechanisms of Lethal Prostate Cancer REQUEST FOR LETTERS OF INTENT / FULL APPLICATIONS IMPORTANT: Applying for a PCF TACTICAL Award (Therapy ACceleration To Intercept CAncer Lethality) involves a 3-stage process. PCF requires a Letter of Intent (LOI), followed by full application submission upon our invitation. Following peer review, top applicants will undergo a Zoom-based interview. The Prostate Cancer Foundation (PCF) is pleased to announce a Request for LOIs for PCF TACTICAL Awards from qualified teams of academic scientists that will specifically address the development of 21st Century therapies for lethal forms of prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world. TACTICAL Awards provide $5 - $10 Million U.S.D. per award over 3-5 years. • Support large-scale research projects concerning metastatic, lethal prostate cancer over a duration of 3-5 years. • Institutional indirect costs of up to 10% will be allowed and should be included as part of the total research budget. • Clinical trial costs are not allowed; however, correlative research to support high impact clinical trials for advanced prostate cancer is encouraged. IRB submission and preferably approval is desired at time of application.

ANNOUNCEMENT: RFA for 2025 PCF TACTICAL Award Letters Of Intent, for multi-institutional research projects to target lethal #ProstateCancer, in 6 specified topic areas.

LOI DEADLINE: May 19, 2025

View RFA: res.cloudinary.com/pcf/images/v...

View LOI form: res.cloudinary.com/pcf/images/v...

Prostate Cancer Foundation 2025 PCF Challenge Awards For Metastatic, Lethal Prostate Cancer REQUEST FOR APPLICATIONS The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world. PCF Challenge Awards: • Composed of a team of at least three (3) investigators from non-profit academic research centers, including one young investigator (see PCF Challenge Award Team requirements below). • Support large-scale research projects concerning metastatic, lethal prostate cancer over a duration of two years. • Provide up to a total of $1 million per team. • Cover only direct research costs and travel to the Annual PCF Scientific Retreat. • Clinical trial direct costs are not allowed; however, correlative research to support high impact clinical trials for advanced prostate cancer is encouraged. IRB submission and preferably approval is desired at time of application. • All studies involving patients must include plans for including diverse participant populations with appropriate representation of ethnic and racial minority groups. Comprehensive statistical plans and power calculations are required. Research proposals in the following topic areas are solicited: • Theranostics. • Drugging currently undruggable oncology targets: preventing progression to lethal disease. • Improved biotechnologies for precision medicine. • First-in-field immunotherapies for prostate cancer. • Artificial intelligence/machine learning to better inform patient outcomes. • Host microbiome and tumor metabolism.

ANNOUNCEMENT: RFA for 2025 @PCFnews team science Challenge Award Applications, to support investigations of metastatic, lethal #ProstateCancer in 6 specified topic areas.

DEADLINE: May 5, 2025

Apply at: pcf.smartsimple.com

View the RFA: res.cloudinary.com/pcf/images/v...

Prostate Cancer Foundation 2025 Young Investigator Awards REQUEST FOR APPLICATIONS The Prostate Cancer Foundation (www.pcf.org) champions investment in human capital to fast-forward solutions for prostate cancer with the ultimate goal of ending death and suffering from metastatic prostate cancer. We continue to focus significant efforts on developing gifted cohorts of young prostate cancer researchers. Since 2007, PCF has awarded 429 PCF Young Investigator Awards in 16 countries, making it one of the most prodigious, productive, competitive and prestigious early career awards in cancer research. We are pleased to announce a new round of funding for PCF Young Investigators. We especially encourage young investigators working on prostate cancer health disparities to apply. The mission of PCF is to fund research addressing unmet medical needs in the diagnosis and treatment of potentially lethal prostate cancer. PCF Young Investigator Awards will be three (3) years in duration and will provide $75,000 per year. The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. This for example, includes funding “protected time” or direct costs for laboratory science. This award does not support indirect costs such as institutional overhead. Every PCF Young Investigator is required to be under the direct supervision of 1-3 mentors. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Forum, typically held in October, throughout the duration of their award.

ANNOUNCEMENT: RFA for 2025 @PCFnews Young Investigator Award Applications, to support innovative & highly promising early career #ProstateCancer researchers.

DEADLINE: March 10, 2025

Apply at: pcf.smartsimple.com

View the RFA here:
res.cloudinary.com/pcf/images/v...

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer This randomized clinical trial explores whether hormone intensification at start of androgen deprivation therapy alters selection of androgen receptor (AR) gene alterations within the gene body and/or...

Latest from #STAMPEDE - intensified AR targeting drives increased prevalence of AR mutations at progression compared to monotherapy patient samples jamanetwork.com/journals/jam...

Grateful for the invitation to give a seminar March 4 at UCLA! Hope to see those there with any interest in prostate cancer, androgen physiology or steroid metabolism! Any chance to talk science these days is particularly therapeutic and a distraction from the distractions. @dgsomucla.bsky.social 🧪

NOW AVAILABLE: The 2024 State of Science Report, which summarizes the scientific presentations from the 2024 @PCFnews Annual Scientific Retreat! #PCFRetreat24

Download to learn about cutting-edge recent advances in #ProstateCancer research & treatment!
www.pcf.org/stateofscien...

Wonderful to have Scott Dehm from University of Minnesota visit Miami - always doing leading edge work in prostate cancer! @pcf-science.bsky.social

Prostate Cancer Foundation 2025 Young Investigator Awards REQUEST FOR APPLICATIONS The Prostate Cancer Foundation (www.pcf.org) champions investment in human capital to fast-forward solutions for prostate cancer with the ultimate goal of ending death and suffering from metastatic prostate cancer. We continue to focus significant efforts on developing gifted cohorts of young prostate cancer researchers. Since 2007, PCF has awarded 429 PCF Young Investigator Awards in 16 countries, making it one of the most prodigious, productive, competitive and prestigious early career awards in cancer research. We are pleased to announce a new round of funding for PCF Young Investigators. We especially encourage young investigators working on prostate cancer health disparities to apply. The mission of PCF is to fund research addressing unmet medical needs in the diagnosis and treatment of potentially lethal prostate cancer. PCF Young Investigator Awards will be three (3) years in duration and will provide $75,000 per year. The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. This for example, includes funding “protected time” or direct costs for laboratory science. This award does not support indirect costs such as institutional overhead. Every PCF Young Investigator is required to be under the direct supervision of 1-3 mentors. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Forum, typically held in October, throughout the duration of their award.

ANNOUNCEMENT: RFA for 2025 @PCFnews Young Investigator Award Applications, to support innovative & highly promising early career #ProstateCancer researchers.

DEADLINE: March 10, 2025

Apply at: pcf.smartsimple.com

View the RFA here:
res.cloudinary.com/pcf/images/v...

Prostate Cancer Foundation logo

PCF Science is now on BlueSky!
Follow us for prostate cancer research news & building the prostate cancer research community.